Welcome to our dedicated page for Inventiva S.A. news (Ticker: IVA), a resource for investors and traders seeking the latest updates and insights on Inventiva S.A. stock.
Inventiva S.A. American Depositary Shares (IVA) represents a France-based biopharmaceutical company focused on research and development in biotechnology. The company’s public communications are reflected in a series of Form 6-K filings that furnish press releases, interim reports and shareholder meeting materials, providing a structured flow of news for investors following IVA.
On this news page, readers can review coverage that aligns with the types of information Inventiva submits to regulators and the market. Form 6-K filings referenced in recent periods include press releases announcing corporate updates, a management report on financial statements for a six-month period, and details related to an Ordinary and Extraordinary General Meeting. News may also highlight capital markets activity, such as the underwriting agreement for a public offering of American Depositary Shares under a shelf registration statement on Form F-3.
Investors tracking IVA can use this page to follow announcements related to Inventiva’s biopharmaceutical research focus, including its work on drug candidates that act on nuclear receptors, transcription factors and epigenetic modulation, and its emphasis on lanifibranor for non-alcoholic steatohepatitis (NASH). Updates connected to its portfolio of pre-clinical programs in oncology, fibrosis and rare diseases may also appear through company press releases and regulatory communications.
This news feed aggregates company-specific items such as press releases furnished on Form 6-K, information about shareholder meetings, and references to the company in third-party announcements, such as mentions of Inventiva’s board representation in other biopharmaceutical organizations. By returning to this page, readers can monitor how Inventiva communicates its research progress, governance events and capital markets transactions over time.
Summary not available.